510(k) DEN200015
DEN200015 is an FDA 510(k) premarket notification submitted by Roche Molecular Systems, Inc. for the device "cobas EBV, cobas EBV/BKV Control Kit, cobas Buffer Negative Control Kit". The FDA issued a decision of De Novo Granted on July 30, 2020. The device falls under product code QLX (Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna), a Class II device regulated under 21 CFR 866.3183. Roche Molecular Systems, Inc. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- DENG (De Novo Granted)
- Decision Date
- July 30, 2020
- Date Received
- March 2, 2020
- Clearance Type
- Direct
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna
- Device Class
- Class II
- Regulation Number
- 866.3183
- Review Panel
- MI
- Submission Type
A quantitative viral nucleic acid test for transplant patient management is identified as a device intended for prescription use in the detection of viral pathogens by measurement of viral deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) using specified specimen processing, amplification, and detection instrumentation. The test is intended for use as an aid in the management of transplant patients with active viral infection or at risk for developing viral infections. The test results are intended to be interpreted by qualified healthcare professionals in conjunction with other relevant clinical and laboratory findings.